Borsò Elisa, Boni Giuseppe, Galli Luca, Ricci Sergio, Farnesi Azzurra, Mazzarri Sara, Cianci Claudia, Mariani Giuliano, Falcone Alfredo
Division of Nuclear Medicine, University Hospital of Pisa, Pisa, Italy.
Future Oncol. 2015;11(2):323-31. doi: 10.2217/fon.14.157. Epub 2014 Jul 30.
The role of nuclear medicine physicians in the multidisciplinary team for the management of patients with prostate cancer has been restricted because of a lack of available tools. The only drugs approved to relieve pain related to bone metastases were β-emitting radiopharmaceuticals. These drugs did not prove to prolong survival when used as single agent and resulted associated with important adverse events. This situation has changed with the introduction of radium 223 because of evidence of improved survival in patients, the good safety profile and the opportunity to avoid clonal selection of tumor cells. Cooperation among physicians involved in cancer management will lead to improvements in the treatment of bone metastases due to prostate cancer and is thought to extend to other tumor types.
由于缺乏可用工具，核医学医师在前列腺癌患者多学科管理团队中的作用受到限制。唯一被批准用于缓解骨转移相关疼痛的药物是发射β射线的放射性药物。这些药物作为单一药物使用时并未证明能延长生存期，且会导致严重不良事件。随着镭223的引入，这种情况发生了变化，因为有证据表明患者生存期得到改善、安全性良好且有机会避免肿瘤细胞的克隆选择。参与癌症管理的医师之间的合作将改善前列腺癌骨转移的治疗，并有望推广到其他肿瘤类型。
